Car-T Cell Therapy: Genetic Engineering and Modern Approaches in Treating Blood Cancer

CAR-T Cell Therapy Genetic Engineering Hematologic Malignancies Immunotherapy CRISPR-Cas9 Cytokine Release Syndrome Allogeneic T-Cells Vector Design

Authors

November 3, 2026

Downloads

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a paradigm shift in oncology, transforming patient care from conventional chemical interventions into highly precise, personalized cellular immunotherapy. Often described as a "living drug," CAR-T cell therapy involves the extraction and genetic modification of a patient’s own T-lymphocytes to express receptors targeted specifically against malignant surface proteins. This article explores the sophisticated manufacturing pipeline of CAR-T cells, evaluates their clinical efficacy in treating hematological malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), addresses the management of severe systemic toxicities, and discusses the future horizons of off-the-shelf allogeneic cell products.